PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS

05 Nov 2026 0 comments

The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.

Source: NeurologyLive Published 04 Nov 2026 Imported 05 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment